Automated Accounts Payable provider Glantus Holdings raises 14M and successfully floats on AIM. Watch the full video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksOncimmune Share News (ONC)

Share Price Information for Oncimmune (ONC)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 222.00
Bid: 214.00
Ask: 222.00
Change: -0.50 (-0.23%)
Spread: 8.00 (3.74%)
Open: 218.50
High: 222.00
Low: 222.00
Yest. Close: 218.50
ONC Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

RNS Alerts are a premium feature

Login to your account

myTerminal is a premium feature

Login to your account

Don't have an account? Click here to register.

IN BRIEF: Oncimmune Signs Autoantibody Profiling Programme Agreement

Wed, 2nd Sep 2020 16:06

Oncimmune Holdings PLC - immunodiagnostics firm - Signa an autoantibody profiling collaboration with an undisclosed biopharmaceutical company. The programme, which is scheduled to complete in the second quarter of 2021, will evaluate the autoantibody profiles from patient samples collected in a clinical trial of a immune checkpoint inhibitor. Such profiling is expected to enable the biopharmaceutical partner to identify better the groups of patients likely to both tolerate a particular immune checkpoint inhibitor treatment and also those whose disease is likely to respond positively to that treatment. Under the agreement, Oncimmune will be utilising its proprietary biomarker discovery engine, SeroTag, to identify tumour associated antibody markers that are predictive of response and immune-related adverse events.

Current stock price: 154.00 pence

Year-to-date change: multiplied

By Evelina Grecenko; evelinagrecenko@alliancenews.com

Copyright 2020 Alliance News Limited. All Rights Reserved.

More News

TRADING UPDATES: SIG in good start to 2021; Accsys taps EUR37 million

TRADING UPDATES: SIG in good start to 2021; Accsys taps EUR37 million

5 May 21 19:20

IN BRIEF: Oncimmune signs separate deals with Roche and Cedars-Sinai

IN BRIEF: Oncimmune signs separate deals with Roche and Cedars-Sinai

6 Apr 21 16:54

Oncimmune secures contracts with Roche and Cedars-Sinai

(Sharecast News) - Immunodiagnostics group Oncimmune said on Tuesday that it had signed two separate agreements for the use of its newly developed and proprietary Infectious Disease panel with Roche Pharmaceuticals and Cedars-Sinai Medical Center.

6 Apr 21 09:14

Oncimmune secures GBP9 million in oversubscribed share placing

Oncimmune secures GBP9 million in oversubscribed share placing

25 Mar 21 16:46

AIM WINNERS & LOSERS: Tandem rises on strong results, positive outlook

AIM WINNERS & LOSERS: Tandem rises on strong results, positive outlook

25 Mar 21 11:28

Oncimmune Interim Loss Narrows On Higher Revenue And Lower Costs

Oncimmune Interim Loss Narrows On Higher Revenue And Lower Costs

15 Feb 21 10:30

UK Earnings, Trading Statements Calendar - Next 7 Days

UK Earnings, Trading Statements Calendar - Next 7 Days

8 Feb 21 16:09

EXECUTIVE CHANGE SUMMARY: Next CEO Wolfson Joins Board Of Deliveroo

EXECUTIVE CHANGE SUMMARY: Next CEO Wolfson Joins Board Of Deliveroo

19 Jan 21 16:30

DIRECTOR DEALINGS: Oncimmune Non-Exec Cheung To Sells 195,000 Shares

DIRECTOR DEALINGS: Oncimmune Non-Exec Cheung To Sells 195,000 Shares

14 Jan 21 14:55

UK TRADING UPDATE SUMMARY: Triple Point Social Ups Credit Facility

UK TRADING UPDATE SUMMARY: Triple Point Social Ups Credit Facility

15 Dec 20 22:00

UK TRADING UPDATE SUMMARY: Novacyt Unveils New Test For Mink Covid

UK TRADING UPDATE SUMMARY: Novacyt Unveils New Test For Mink Covid

14 Dec 20 22:04

Oncimmune signs two NHS contracts, has NICE guidance published

(Sharecast News) - Oncimmune has signed a commercial contract to supply its 'EarlyCDT Lung' blood test to NHS Norfolk & Waveney Clinical Commissioning Group, it announced on Monday.

14 Dec 20 14:54

UK Shareholder Meetings Calendar - Next 7 Days

UK Shareholder Meetings Calendar - Next 7 Days

16 Nov 20 16:03

UK TRADING UPDATE SUMMARY: Mereo To Delist From AIM Amid Nasdaq Focus

UK TRADING UPDATE SUMMARY: Mereo To Delist From AIM Amid Nasdaq Focus

11 Nov 20 20:17

Oncimmune enters deal with Augmenta to profile plasma samples

(Sharecast News) - Immunodiagnostics group Oncimmune has signed a new master service agreement with Augmenta Bioworks, it announced on Wednesday, to profile patient plasma samples and characterise therapeutic candidates discovered through Augmenta's 'SingleCyte' and 'DeepGrid' discovery platforms.

11 Nov 20 10:13

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.